However, the use of PDE3 inhibitors could become clinical practice even for patients with severe HF, i.e., targeting PDE3 or other PDE isoforms specifically in the vasculature without promoting cardiac toxicity. This evidence concerns the gene ALDH7A1 and hydrops fetalis.